GlassScriptPhysician profile
Iryna O Kinzer
NPI 1003380593
$7,335.19
in general payments reported to CMS, 2019-2025
20 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $551 · 2023: $1,368 · 2024: $2,587 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,118.65 |
| Education | $315.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,520.11 | 2021-2025 | |
| Genzyme Corporation | $1,475.22 | 2021-2025 | |
| Janssen Biotech, INC. | $1,083.97 | 2022-2025 | Tremfya, Remicade, Simponi |
| Ucb, INC. | $575.84 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $508.43 | 2021-2025 | |
| Amgen INC. | $484.41 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $364.99 | 2023-2024 | Vtama |
| Leo Pharma INC. | $220.89 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $170.91 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $156.26 | 2025 | Zoryve |
| Pfizer INC. | $123.70 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $119.36 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $114.67 | 2024-2025 | |
| Organon LLC | $97.23 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.76 | 2024-2025 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $77.30 | 2024-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Verrica Pharmaceuticals INC. | $50.72 | 2024 | Ycanth |
| Incyte Corporation | $18.65 | 2025 | Opzelura |
| Phadia US INC. | $17.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iryna Kinzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.